沙利度胺联合多西他赛治疗晚期非小细胞肺癌的临床观察  

A clinical study of thalidomide combined with docetaxel,as the second line treatment of advanced non-small-cell lung cancer

作　　者：张广杰[1] 艾冬梅[1] 王欣[1] 俞宏伟[1] 张健[1] 

机构地区：[1]衡水市第二人民医院肿瘤科,河北衡水053000

出　　处：《现代肿瘤医学》2008年第12期2094-2096,共3页Journal of Modern Oncology

摘　　要：目的:观察反应停联合多西他赛(多西紫杉醇)二线治疗晚期非小细胞肺癌患者的疗效及其对生活质量的影响。方法:对60例复发的晚期非小细胞肺癌(NSCLC)患者采用完全随机分组的方法,分为治疗组:反应停联合多西他赛方案30例,(反应停第1周100mg/d,晚睡前顿服日1次,第2周开始增加至300mg/d,并以300mg/d为维持剂量,至少口服2个月以上;多西他赛35mg/m2,静滴1小时,第1、8、15天;对照组:多西他赛单药方案,用法同治疗组。结果:反应停联合多西他赛组和多西他赛单药组有效率分别为26.6和20.0;临床受益率(CR+PR+SD),治疗组高于对照组(66.7vs50.0),两组相比,差异无显著性P>0.05(P=0.2918)。两者中位TTP分别为4.7个月和4.2个月,中位生存期分别为7.2个月和6.3个月,治疗组优于对照组,但P>0.05。毒性反应,两组相比,无显著性差异(P>0.05)。生活质量方面,治疗组患者食欲及体重明显优于对照组(P<0.05)。结论:反应停联合多西他赛二线治疗晚期非小细胞肺癌能增加疗效,改善患者生活质量。Objective：To observe the efficacy of thalidomide combined with docetaxel （DOC） as the second line treatment of advanced non - small - cell lung cancer. Methods： A total of 60 patients was randomly divided into two groups, study group with thalidomide combined with DOC regimen, and control group treated with DOC regimen. Re- suits： For the treatment group and the control group, the recent efficient rates were 26.6% and 20%, CR ＋ PR ＋ SD of two groups were 66.7% and 50. 0%. The median time to progress was 4.7 months and 4.2 months,the medan survival was 7.2 months and 6.3 months respectively,P 〉 0.05. Patientsin the treatment group were promoted in diet and weight, there was significantly difference between the two groups （P 〈 0.05）. Conclusion： Thalidomide regimen in second - line treatment for the advanced non - small - cell lung cancer is an effective regimen, and it can elevate life quality.

关 键 词：反应停 多西他赛 晚期非小细胞肺癌 二线治疗 

分 类 号：R734.2[医药卫生—肿瘤]